Clarithromycin Shortage: A Provider Briefing for 2026

Clarithromycin remains a cornerstone of outpatient antibiotic therapy. As a macrolide with reliable activity against common respiratory pathogens, atypical organisms, and Helicobacter pylori, it's a drug that many providers reach for regularly — which makes supply disruptions particularly impactful.

This briefing provides an up-to-date assessment of Clarithromycin availability, prescribing considerations, and practical resources for managing patient access in 2026.

Current Supply Status and Timeline

As of Q1 2026, Clarithromycin is not listed on the FDA Drug Shortage Database or the ASHP Current Drug Shortages list. National supply from generic manufacturers (including Teva, Sandoz, and Mylan) appears stable.

However, providers should be aware of several factors that can cause localized disruptions:

• Seasonal demand surges: Clarithromycin prescribing volume increases 30-50% during peak respiratory season (October–March). Pharmacies using just-in-time inventory systems may deplete stock faster than distributors can replenish.
• Distributor-level variability: Different pharmacy chains source from different wholesalers. A supply hiccup at one distributor can create apparent shortages at certain chains while others remain fully stocked.
• API sourcing concentration: Active pharmaceutical ingredients for generic Clarithromycin are predominantly manufactured in India and China. Regulatory actions, factory inspections, or export restrictions at these facilities can cause downstream supply interruptions.

Historically, Clarithromycin has not experienced the kind of prolonged, market-wide shortages seen with medications like Amoxicillin (2022-2023) or Adderall. Past disruptions have been intermittent and typically resolved within weeks.

Prescribing Implications

When Clarithromycin Is Preferred

Clarithromycin remains specifically indicated in several clinical scenarios where alternatives are less optimal:

• H. pylori eradication: Clarithromycin-based triple therapy (with Amoxicillin and a PPI) remains a first-line regimen per ACG guidelines, provided local Clarithromycin resistance rates are below 15%.
• MAC prophylaxis and treatment: In patients with advanced HIV (CD4 < 50), Clarithromycin is preferred over Azithromycin for MAC treatment due to superior bactericidal activity.
• Extended-release formulation advantages: Biaxin XL's once-daily dosing improves adherence for patients who struggle with twice-daily regimens.

When Alternatives Are Equivalent or Preferred

For many common indications, switching to an alternative is clinically straightforward:

• Community-acquired pneumonia: Azithromycin (500 mg day 1, then 250 mg days 2-5) provides equivalent coverage of typical and atypical pathogens with better tolerability and fewer drug interactions.
• Acute sinusitis/bronchitis: Amoxicillin-clavulanate or Doxycycline are appropriate alternatives. For mild cases, many guidelines now recommend watchful waiting before prescribing antibiotics.
• Pharyngitis: Penicillin V or Amoxicillin remain first-line for Group A strep. Clarithromycin is typically reserved for penicillin-allergic patients.

For a patient-facing overview of alternatives, see our article on alternatives to Clarithromycin.

Drug Interaction Considerations

Clarithromycin is a potent inhibitor of CYP3A4 and P-glycoprotein, which creates clinically significant interactions with numerous medications. When supply issues prompt a switch, this may actually benefit patients on complex regimens:

• Statins: Simvastatin and Lovastatin are contraindicated with Clarithromycin. Azithromycin has no such restriction.
• Anticoagulants: Clarithromycin significantly increases Warfarin INR. Monitor closely or prefer Azithromycin.
• Immunosuppressants: Clarithromycin increases levels of Cyclosporine, Tacrolimus, and Sirolimus. Consider Azithromycin in transplant patients.
• Cardiac medications: The 2018 FDA safety communication warned of increased cardiovascular mortality risk in patients with heart disease. For patients with coronary artery disease, alternatives should be strongly considered regardless of supply availability.

For comprehensive interaction data, refer patients to our guide on Clarithromycin drug interactions.

Availability Picture Across Settings

Availability varies by pharmacy type:

• Large chain pharmacies (CVS, Walgreens, Rite Aid): Most likely to experience temporary stock-outs during peak season due to centralized ordering systems.
• Independent pharmacies: Often use multiple wholesalers and can source more flexibly. May have stock when chains don't.
• Hospital outpatient pharmacies: Typically maintain broader stock and may be a reliable source for patients with urgent needs.
• Mail-order and online pharmacies: Amazon Pharmacy, Cost Plus Drugs, and similar services generally maintain stable generic antibiotic supply.

Cost and Access Considerations

Clarithromycin remains affordable as a generic medication:

• Average retail cash price: $80–$150 for a 14-day course (500 mg BID)
• With discount coupons (GoodRx, SingleCare): $16–$25
• Typical insurance copay: $5–$20 (Tier 1 or 2 generic)

Prior authorization is generally not required for generic Clarithromycin. Medicare Part D and Medicaid plans cover it without step therapy. For uninsured patients, prescription discount cards provide substantial savings.

For patients experiencing financial barriers, see our resource on helping patients save money on Clarithromycin.

Tools and Resources for Your Practice

Several tools can help you and your patients navigate availability challenges:

• Medfinder for Providers: medfinder.com/providers offers real-time pharmacy availability data that you can share with patients or use to direct them to pharmacies with confirmed stock.
• FDA Drug Shortage Database: accessdata.fda.gov/scripts/drugshortages — for monitoring official shortage status.
• ASHP Drug Shortages Resource Center: ashp.org/drug-shortages — comprehensive shortage tracking with clinical alternatives.
• GoodRx Price Comparison: Useful to share with uninsured patients to find the lowest local price.

Looking Ahead

No significant supply disruptions for Clarithromycin are anticipated through the remainder of 2026. The generic market is served by multiple manufacturers, and demand patterns are predictable.

Key factors to monitor:

• Any FDA enforcement actions at API manufacturing facilities
• Severity of the upcoming respiratory illness season
• Changes in H. pylori treatment guidelines that could shift prescribing patterns
• Generic manufacturer market exits (low margins remain a chronic concern for the generic antibiotic sector)

Final Thoughts

Clarithromycin supply in 2026 is generally stable, but providers should be prepared for localized availability gaps — particularly during respiratory season. Having alternative prescribing strategies ready and directing patients to availability tools like Medfinder can minimize treatment delays.

For patient-facing resources, consider sharing our articles on finding Clarithromycin in stock and the patient shortage update to help set expectations and reduce unnecessary callbacks to your office.